Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 157-167

  Levitan, Bennett ^a   Yuan, Zhong ^a   Turpie, Alexander G G ^b   Friedman, Richard J ^c   Homering, Martin ^d   Berlin, Jesse A ^a   Berkowitz, Scott D ^e   Weinstein, Rachel B ^a   DiBattiste, Peter M ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c Charleston Orthopaedic Associates   (United States)

^d BAYER PHARMA AG   (Germany)

^e BAYER CORPORATION   (United States)

Author keywords

DVT; PE; Thromboprophylaxis; Total hip arthroplasty; Total knee arthroplasty; VTE

Indexed keywords

ENOXAPARIN; RIVAROXABAN;

ADULT; ARTICLE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OPERATIVE BLOOD LOSS; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURGICAL MORTALITY; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

DVT; PE; THROMBOPROPHYLAXIS; TOTAL HIP ARTHROPLASTY; TOTAL KNEE ARTHROPLASTY; VTE;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; HEMORRHAGE; HUMANS; MORPHOLINES; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84898017504     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S54714     Document Type: Article

References (39)

1. Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty: Evidence-Based Guideline and Evidence Report. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2011. Available from: http://www.aaos.org/research/guidelines/VTE/VTE_full_guideline.pdf. Accessed October 1, 2013.
2. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I22-I30.
3. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002;162(10):1144-1148.
4. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004;164(1): 17-26.
5. Lang I, Kerr K. Risk factors for chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3(7):568-570.
6. Pengo V, Lensing AWA, Prins MH, etal. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264.
7. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest. 2009;135(2):513-520.
8. Falck-Ytter Y, Francis CW, Johanson NA, etal. American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e278S-e325S.
9. Warwick D, Friedman RJ, Agnelli G, etal. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007;89(6):799-807.
10. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e44S-e88S.
11. Eriksson BI, Borris LC, Friedman RJ, etal; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
12. Kakkar AK, Brenner B, Dahl OE, etal; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39.
13. Lassen MR, Ageno W, Borris LC, etal; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
14. Turpie AGG, Lassen MR, Davidson BL, etal; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676): 1673-1680.
15. Turpie AGG, Lassen MR, Eriksson BI, etal. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost. 2011;105(3):444-453.
16. Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther. 2011;89(2):312-315.
17. Benefit-risk methodology [webpage on the Internet]. London: European Medicines Agency; 2011. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp&mid=WC0b01ac0580223ed6&murl=menus/special_topics/special_topics.jsp&jsenabled=true. Accessed July 16, 2013.
18. Levitan BS, Andrews EB, Gilsenan A, etal. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011;89(2):217-224.
19. Structured Approach to Benefit-Risk Assessment in drug Regulatory Decision-Making. US Food and Drug Administration; 2013. Available from: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf. Accessed September 2, 2013.
20. Benefit-risk integration and representation [webpage on the Internet]. PROTECT Investigators Innovative Medicines Initiative. Available from: http://www.imi-protect.eu/benefitPres.shtml. Accessed July 16, 2013.
21. Walker S, Liberti L, McAuslane N, Levitan BS. Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters. Clin Pharmacol Ther. 2011;89(2):179-182.
22. Bauer KA, Turpie AGG, Lassen MR, Kakkar AK, Eriksson BI, Gent M; RECORD 1-4 Investigators. Effects of age, weight, gender and renal function in a pooled analysis of four rivaroxaban studies. J Thromb Haemost. 2009;7(S2):767:PP-WE-421.
23. Eriksson BI, Kakkar AK, Turpie AGG, etal. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009;91(5):636-644.
24. Beasley BN, Unger EF, Temple R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788-1790.
25. Gibson CM, Levitan B, Murphy SA, etal. A net clinical outcome analysis comparing fatal or irreversible ischemic and bleeding events in ATLAS ACS 2-TIMI 51. Circulation. 2012;126:A13152.
26. Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost. 2009;15(4):377-388.
27. Kaul S, Diamond GA. Does rivaroxaban provide a clinically relevant favorable benefit-risk profile compared with enoxaparin after hip or knee arthroplasty? J Am Coll Cardiol. 2010;55(10):E1616-E1618: A172.
28. Levitan B, Yuan Z, Turpie AGG, etal. Quantitative benefit-risk assessment of rivaroxaban for the prevention of venous thromboembolism. Blood (ASH Annual Meeting Abstracts). 2009;114(22):75-76:A169.
29. Singer DE, Chang Y, Fang MC, etal. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5): 297-305.
30. Unger EF. Weighing benefits and risks-the FDA's review of prasugrel. N Engl J Med. 2009;361(10):942-945.
31. Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost. 2009;15(4):389-394.
32. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675.
33. Advisory Committee Briefing Book: Rivaroxaban for the Prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Patients Undergoing Hip or Knee Replacement Surgery. Johnson & Johnson Pharmaceutical Research and Development, LLC; 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM138385.pdf. Accessed September 2, 2013.
34. Lassen MR, Gent M, Kakkar AK, etal. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. J Bone Joint Surg Br. 2012;94(11): 1573-1578.
35. Cushner F, Agnelli G, FitzGerald G, Warwick D. Complications and functional outcomes after total hip arthroplasty and total knee arthroplasty: results from the Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010;39(Suppl 9):22-28.
36. Jameson SS, Rymaszewska M, James P, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am. 2012;94(17):1554-1558.
37. Jensen CD, Steval A, Partington PF, Reed MR, Muller SD. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br. 2011;93(1):91-95.
38. Chan CM, Zilberberg MD. Preferences in traumatic intracranial hemorrhage: bleeding vs. clotting. Crit Care. 2010;14(3):153.
39. Lip GYH, Piotrponikowski P, Andreotti F, etal. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. An Executive Summary of a joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost. 2012;108(6): 1009-1022.